Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2014; 20(4): 968-977
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.968
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.968
Cysteinyl leukotrienes and their receptors: Bridging inflammation and colorectal cancer
Sayeh Savari, Katyayni Vinnakota, Yuan Zhang, Anita Sjölander, Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden
Author contributions: Savari S and Vinnakota K contributed equally to this work; all authors discussed, read and approved the manuscript.
Correspondence to: Anita Sjölander, Professor, Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Jan Waldenströms gata 35, SE-205 02 Malmö, Sweden. anita.sjolander@med.lu.se
Telephone: +46-40-391168 Fax: +46-40-391177
Received: October 6, 2013
Revised: November 16, 2013
Accepted: December 5, 2013
Published online: January 28, 2014
Revised: November 16, 2013
Accepted: December 5, 2013
Published online: January 28, 2014
Core Tip
Core tip: Despite several advances in diagnostic and therapeutic options, colorectal cancer (CRC) continues to be a major health problem and one of the leading causes of cancer-related deaths. The inflammatory milieu has been widely recognized as one of the enabling characteristics of cancer development. Cysteinyl leukotrienes are pro-inflammatory eicosanoids implicated in chronic inflammatory bowel diseases and CRC development. Hence, targeting cysteinyl leukotrienes and their receptors could provide alternative therapeutic approaches or be used in combination with existing therapies for more efficient treatment of CRC.